Table 3.

Polymorphisms of IGF1 and IGFBP3 genes and NSCLC patients’ survival

LocusGenotypePatientsDeathsMST (mo)Log-rank PCrude HR (95% CI)Adjusted HR (95% CI)*
IGF1 rs5742714n = 547n = 301
    Codominant modelCC37721923.01.001.00
CG1537628.20.77 (0.60-1.01)0.82 (0.63-1.08)
GG17626.50.0430.54 (0.24-1.21)0.48 (0.21-1.10)
    Dominant modelCC37721923.01.001.00
CG/GG1708228.50.0170.74 (0.57-0.95)0.77 (0.60-0.99)
    Recessive modelCC/CG53029524.31.001.00
GG17626.50.1630.57 (0.25-1.27)0.50 (0.22-1.12)
    Additive modelG allele0.75 (0.60-0.94)0.77 (0.61-0.96)
Trend P0.0100.023
IGFBP3 rs2132572n = 568n = 311
    Codominant modelGG36619425.91.001.00
AG1789724.81.19 (0.93-1.51)1.04 (0.81-1.34)
AA242016.70.0052.07 (1.31-3.30)1.43 (0.90-2.29)
    Dominant modelGG36619425.91.001.00
AG/AA20211722.10.0371.28 (1.02-1.61)1.09 (0.86-1.39)
    Recessive modelGG/AG54429125.91.001.00
AA242016.70.0031.96 (1.25-3.10)1.39 (0.88-2.20)
    Additive modelA allele1.31 (1.08-1.58)1.12 (0.92-1.36)
Trend P0.0060.247
IGFBP3 rs10255707n = 565n = 309
    Codominant modelGG38320025.51.001.00
AG1619524.81.20 (0.94-1.53)1.03 (0.80-1.32)
AA211415.00.0461.84 (1.07-3.16)1.47 (0.84-2.56)
    Dominant modelGG38320025.51.001.00
AG/AA18210923.10.0601.25 (0.99-1.58)1.08 (0.84-1.37)
    Recessive modelAA/AG54429525.11.001.00
AA211415.00.0421.74 (1.01-2.97)1.47 (0.85-2.54)
    Additive modelA allele1.26 (1.03-1.54)1.11 (0.90-1.36)
Trend P0.0230.338
  • *Adjusted for age, gender, smoking status, histology, stage, surgical operation, and chemotherapy or radiotherapy status.

  • Mean survival time was provided when MST could not be calculated.

  • Assuming an additive effect of the variant alleles.